EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)ÄquivalenzstudieMultizentrische StudieRandomisierte kontrollierte Studie

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer

Kohei Shitara iD, Elena Elimova, Tianshu Liu, Josep Tabernero, Keun-Wook Lee, Michael Schenker, Niall C Tebbutt, Jaffer Ajani iD, Norhidayu Salimin, Geoffrey Ku, Jong Gwang Kim, Inmaculada Ales Diaz und 18 weitere

New England Journal of Medicine · 28.05.2026 · 394 (20) · 2002-2014

DOI: 10.1056/nejmoa2517729 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 28.05.2026. Verfasst von Kohei Shitara und 29 weiteren Autor:innen. Beteiligte Einrichtung: National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Adenocarcinoma, Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: BeOne Medicines, Jazz Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenocarcinomaAntibodies, BispecificAntineoplastic Combined Chemotherapy ProtocolsEsophageal NeoplasmsStomach NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalDiarrheaErb-b2 Receptor Tyrosine KinasesEsophagogastric JunctionFollow-Up StudiesImmune Checkpoint InhibitorsIncidenceKaplan-Meier EstimateProgression-Free SurvivalTime FactorsTrastuzumab

Substanzen

Antibodies, BispecificAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalErb-b2 Receptor Tyrosine KinasesERBB2 protein, humanImmune Checkpoint InhibitorstislelizumabTrastuzumabzanidatamabCombined Antibody Therapeutics

Autor:innen und Institutionen

  • National Cancer Center Hospital East, Kashiwa, Japan.
  • Princess Margaret Cancer Centre, Toronto.
  • Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai.
  • Vall d'Hebron Hospital Campus, Barcelona.
  • Vall d'Hebron Institute of Oncology, Barcelona.
  • Vall d'Hebron Institut de Recerca, Barcelona.

ORCID-Profile: Kohei Shitara, Jaffer Ajani

Förderung

  • BeOne Medicines
  • Jazz Pharmaceuticals

Zitieren

APA

Shitara, K., Elimova, E., Liu, T., Tabernero, J., Lee, K. W., Schenker, M., Tebbutt, N. C., Ajani, J., Salimin, N., Ku, G., Gwang Kim, J., Ales Diaz, I., Zhang, J., Pietrantonio, F., Bai, L. Y., Le Sourd, S., Zhao, J., Hierro, C., Kiberu, A., …, & HERIZON-GEA-01 Investigators (2026). Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. New England Journal of Medicine, 394(20), 2002-2014. https://doi.org/10.1056/nejmoa2517729

Vancouver

Shitara K, Elimova E, Liu T, Tabernero J, Lee KW, Schenker M, et al. Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer. New England Journal of Medicine. 2026;394(20):2002-2014. doi:10.1056/nejmoa2517729

BibTeX
@article{Shitara2026,
  author = {Shitara, Kohei and Elimova, Elena and Liu, Tianshu and Tabernero, Josep and Lee, Keun-Wook and Schenker, Michael and Tebbutt, Niall C and Ajani, Jaffer and Salimin, Norhidayu and Ku, Geoffrey and Gwang Kim, Jong and Ales Diaz, Inmaculada and Zhang, Jingdong and Pietrantonio, Filippo and Bai, Li-Yuan and Le Sourd, Samuel and Zhao, Jun and Hierro, Cinta and Kiberu, Andrew and Van Herpe, Filip and Bao, Yuanyuan and Zhang, Hanze and Yang, Lin and Li, Vincent and Gartner, Elaina M and Chen, Ye and Grim, Jonathan and Rha, Sun Young and Shen, Lin and HERIZON-GEA-01 Investigators, HERIZON-GEA-01 Investigators},
  title = {Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {20},
  pages = {2002--2014},
  doi = {10.1056/nejmoa2517729}
}
Kostenlos starten →